ADVFN - Advanced Financial Network.
HOME» NYSE » M » MRK Stock Price » MRK Stock News

Merck Share News

 Merck & Co., Stock Price
MRK Stock Price
 Merck & Co., Stock Chart
MRK Stock Chart
 Merck & Co., Stock News
MRK Stock News
 Merck & Co., Company Information
MRK Company Information
 Merck & Co., Stock Trades
MRK Stock Trades

Ligand: Glaxo Receives Priority Review for Eltrombopag's Supplemental NDA

By Victoria Stilwell Ligand Pharmaceuticals Inc. (LGND) said the U.S. Food and Drug Administration granted its partner, GlaxoSmithKline PLC (GSK), priority review of the supplemental new drug application for its eltrombopag drug, which treats thrombocytopenia in patients with chronic hepatitis C virus infection. Eltrombopag, known by the brand name Promacta in the U.S., is currently approved in 89 countries as a treatment for patients with chronic immune thrombocytopenia. Thrombocytopenia is a condition in which a patient's blood has a lower-than-normal number of platelets, allowing mild to serious bleeding to occur inside the body or underneath or from the skin. The drug is used to increase the number of cells that help the blood clot in order to decrease the risk of bleeding. Ligand is a biopharmaceutical company that aims to develop or acquire diverse, royalty-revenue-generating assets and couple them with a lean corporate cost structure. Ligand has also partnerships with companies including Merck & Co. (MRK), Pfizer Inc. (PFE) and Eli Lilly & Co. (LLY). Shares of Ligand closed Tuesday at $17.61 and were inactive in premarket trade. The stock is up 48% so far this year. Write to Victoria Stilwell at Victoria.Stilwell@dowjones.com Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stock News for Merck (MRK)
DateTimeHeadline
07/01/201516:36:01Statement of Changes in Beneficial Ownership (4)
07/01/201516:36:01Statement of Changes in Beneficial Ownership (4)
07/01/201516:36:01Statement of Changes in Beneficial Ownership (4)
07/01/201516:36:01Statement of Changes in Beneficial Ownership (4)
07/01/201516:36:01Statement of Changes in Beneficial Ownership (4)
06/29/201509:27:34Merck Regimen to Reduce Nausea Meets Primary Endpoint
06/29/201508:30:00Merck Announces Phase 3 Study of Single-Dose EMEND® (fosaprepitant...
06/29/201508:00:00Sanofi Pasteur and Merck Vaccines Appoint David Khougazian as...
06/26/201508:00:00Merck to Hold Second-Quarter 2015 Sales and Earnings Conference...
06/21/201511:06:03What Is Cancer Immunotherapy?
06/19/201507:58:02Why Bristol-Myers Squibb Co.'s Stock Could Sink
06/18/201516:40:12Annual Report of Employee Stock Plans (11-k)
06/18/201516:37:36Annual Report of Employee Stock Plans (11-k)
06/18/201516:35:51Annual Report of Employee Stock Plans (11-k)
06/17/201517:43:42Inspire Pharmaceuticals Settles Federal Fraud Claims
06/15/201514:50:04EU Approves Merck KGaA $17 Billion Purchase of Sigma-Aldrich
06/15/201510:14:59Is Medicare in Danger from Free Trade?
06/13/201513:16:02Why I'm Shorting Biotech
06/11/201509:00:00Liaison Technologies and Merck Cut the Ribbon for a Collaborative...
06/11/201508:00:00Merck Launches New Program That Encourages Women to "Rule the...

Merck and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad